PURPOSE: Approximately 5 to 10 percent of patients undergoing ileal pouch-anal anastomosis with a diagnosis of ulcerative colitis are subsequently diagnosed with Crohn's disease. Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined.
METHODS: A total of 238 consecutive patients with ulcerative colitis or indeterminate colitis undergoing ileal pouch-anal anastomosis were prospectively enrolled into a longitudinal database. Clinical factors were assessed perioperatively. Serum drawn preoperatively was assayed for anti-Saccharomyces cerevisiae, antiouter membrane porin-C, anti-CBir1, and perinuclear antineutrophil cytoplasmic antibody using enzyme-linked immunosorbent assay. Crohn's disease was defined by small bowel inflammation proximal to the ileal pouch or a perianal fistula identified at least three months after ileostomy closure. Predictors were assessed in a multivariate Cox proportional hazards model to predict the rate of Crohn's disease after ileostomy closure.
RESULTS: Sixteen patients (7 percent) were diagnosed with Crohn's disease; median time to Crohn's disease was 19 (range, 1-41) months. Significant factors for postoperative Crohn's disease after ileal pouch-anal anastomosis included family history of Crohn's disease (hazard ratio, 8.4 ; 95 percent confidence interval, 2.96-24.1; P<0.0001) and anti-Saccharomyces cerevisiae immunoglobulin-A seropositivity (hazard ratio, 3.14; 95 percent confidence interval, 1.1-9.81; P=0.04). Crohn's disease developed in only 8 of 198 patients (4 percent) without these predictors vs. 8 of 40 patients (20 percent) in those with at least one of these factors (P=0.002). The cumulative risk of Crohn's disease among patients with two risk factors (67 percent) was higher than in patients with either risk factor (18 percent) or neither risk factor (4 percent, P<0.001).
CONCLUSIONS: Patients with ulcerative colitis and indeterminate colitis with a family history of Crohn's disease or preoperative anti-Saccharomyces cerevisiae immunoglobulin-A seropositivity are more likely to be diagnosed with Crohn's disease after ileal pouch-anal anastomosis.
KEY WORDS: Ileal pouch-anal anastomosis; Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; Indeterminate colitis; Serology; pANCA; ASCA; OmpC. I leal pouch-anal anastomosis (IPAA) has become the standard operative approach for patients requiring colectomy for ulcerative colitis (UC) or in selected patients with indeterminate colitis (IC). Despite excellent functional results and high patient satisfaction, 1,2 approximately 5 to 10 percent of patients develop Crohn's disease (CD) of the pouch. [3] [4] [5] [6] [7] [8] Although many patients with CD of the pouch can be effectively treated medically, some require local remedial surgery or permanent fecal diversion. 9, 10 Although there is a body of literature examining the outcome of patients with CD who undergo IPAA, 11, 12 little is known about the development of postoperative CD after IPAA for patients with UC or IC. Several retro-spective studies have attempted to identify risk factors for the development of CD. 8, [13] [14] [15] [16] A recent prospective clinical analysis identified that both a longer duration of IPAA and smoking were potential risk factors for CD of the pouch. 17 However, this study is limited by referral center bias at a specialized "Pouchitis Clinic." Serologic immune markers have been associated with inflammatory bowel disease (IBD). Perinuclear antineutrophil cytoplasmic antibodies (pANCA) are found in 60 to 80 percent of patients with UC. [18] [19] [20] P-ANCA also is present in 15 to 25 percent of patients with CD, in whom it is associated with a "UC-like" clinical picture. 21 Anti-Saccharomyces cerevisiae antibodies (ASCA) are found in approximately 60 percent of patients with CD. 22, 23 Although serum pANCA and ASCA are the best studied serologic markers for IBD, antibodies against the outer membrane porin C (anti-OmpC) of Escherichia coli and anti-CBir1 also are found in approximately 50 percent of patients with CD and to a lesser degree in patients with UC. 24, 25 The value of these disease markers in predicting CD development after IPAA has not been defined.
In this prospective study, we investigated the association of preoperative clinical and serologic factors with the development of CD after IPAA in a longitudinally followed cohort of consecutive patients with UC and IC operated on by a single surgeon.
PATIENTS AND METHODS

Study Population
Consecutive patients with UC or IC requiring colectomy for medically unresponsive disease or dysplasia during the eight-year period ending December 2005 were studied. All research-related activities were approved by the Cedars-Sinai Medical Center Institutional Review Board. Complete mucosectomy was performed in all patients. All patients had a temporary diverting ileostomy constructed at the time of pouch creation. Patients were seen for follow-up examinations (including pouchoscopy) every three months for the first year after stoma closure and yearly thereafter.
Assessment of Clinical Characteristics
Detailed clinical profiles assessing demographic information and characteristics of the disease and its treatment were prospectively collected by using chart review and patient interview immediately after colectomy and at routine postoperative visits. Demographic information included patient age at surgery, gender, smoking history, and length of follow-up after surgery. Patients who smoked at the time of surgery and/or after colectomy were considered to be smokers. Both current smokers and ex-smokers comprised the smoking patient group. Disease characteristics examined included disease duration and extent, presence of extraintestinal manifestations (EIM), backwash ileitis, detailed family history of inflammatory bowel disease (IBD), and type of colitis (UC vs. IC). Disease duration referred to the time interval between IBD diagnosis and the date of colectomy. Anatomic location of disease was grouped postoperatively into categories of pancolitis, leftsided colitis, and proctitis. EIMs noted before colectomy included primary sclerosing cholangitis (PSC), skin lesions (pyoderma gangrenosum, erythema nodosum), bone/joint disease (arthritis, ankylosing spondylitis, sacroileitis), or eye disease (uveitis, episcleritis) considered by the investigators and the patients' physicians to be manifestations of IBD. The diagnosis of PSC was based on clinical findings and confirmed with liver biopsy and/or ERCP. Backwash ileitis was defined by macroscopic or histologic inflammation restricted to the distal 3 cm of the terminal ileum not thought to be CD. Treatment characteristics included the nature of medical therapy before colectomy (steroids alone vs. the use of other immunomodulators) and the indications for surgery (medically refractory disease vs. dysplasia/cancer). Blood drawn on the day before surgery was analyzed for platelet count (normal range, 150×10 9 /L to 450×10 9 /L) using standard automated laboratory techniques.
Family History of IBD Family history was initially obtained by patient interview and confirmed among those patients who consented for separate genetics investigation at Cedars-Sinai Medical Center. When relatives reported to have UC or CD were not participants in our local genetics projects or not patients of our own hospital, we evaluated their diagnoses by asking the index patients detailed information regarding the symptoms, treatment, and course of disease in their relatives. Only relatives in whom we could confirm a diagnosis of UC or CD were regarded as having either disease. A patient with a family history of both UC and CD would be considered to have both a family history of IBD and a family history of CD. Because of the stronger genetic influence from first-degree relatives (in contrast with that from more distant family members), an individual "family history score" (FHS) was calculated as follows: FHS = [2× (number of affected first-degree relatives) + 1× (number of second-degree relatives)]. FHS for a group of patients was calculated by dividing the aggregate FHS sum by the total number of patients in that group. This scoring measure was designed to provide a greater weight to the potential genetic influence from a first-degree relative. Thus, a patient with an affected parent (first-degree relative) and uncle (second-degree relative) would have an FHS=3, whereas a patient with two affected siblings but no other affected relatives would have an FHS=4. FHS was not included in the multivariate model.
Diagnosis of Ulcerative and Indeterminate Colitis
Clinical, endoscopic, and pathologic criteria were reviewed in all patients to determine if they were UC, IBD-U, or IC. MELMED ET AL.: RISK FACTORS FOR CD AFTER ILEAL POUCH SURGERY Clinically, patients with UC had no perianal disease, and endoscopic and histologic features included continuous inflammation extending proximally from the dentate line. All patients underwent radiologic evaluation with small-bowel follow-through to exclude small-bowel disease. Patients with histologic granulomata were excluded. Additionally, the diagnosis was revisited on review of intraoperative findings and pathologic evaluation of the resected specimen. Using the Montreal classification, 26 patients were classified as having IBD-type unclassified (IBD-U) or postoperative IC when they had clinical features of UC with some features suggestive but not diagnostic of CD. Preoperative features of IBD-U included skip lesions possibly related to medical therapy, distant history of an anal fistula or ulcer, or small-bowel inflammation more than 3 cm proximal to the ileocecal valve. Postoperative features of IC included gross or microscopic transmural colonic inflammation or discontinuous histologic involvement of the colon possibly related to medical therapy. We used an inclusive definition of postoperative IC that included all patients with IBD-U in addition to those patients with UC that were reclassified as IC on the basis of colectomy specimen. Patients with extensive small-bowel inflammation, active anal disease, or those with granulomatous inflammation on histopathologic examination were deemed to have CD and were excluded from study analysis.
Diagnosis of Crohn's Disease after Surgery
CD after IPAA was diagnosed when mucosal inflammation (5 or more ulcers) involved the small-bowel mucosa proximal to the ileal pouch any time after surgery and/or when a pouch fistula or other perianal complication developed more than three months after ileostomy closure. 27 Stool studies were obtained in all cases to exclude infection. Time to diagnosis of CD was defined as the time period from ileostomy closure. Patients in whom the ileostomy was not closed, those who did not consent to have blood drawn for research purposes, and those using nonsteroidal anti-inflammatory drugs were excluded from analysis.
Serologic Analysis
Serum was drawn immediately before colectomy, coded, and stored for future analysis. All sera were analyzed in a blinded fashion by Prometheus Laboratories (San Diego, CA) or performed at Cedars-Sinai Medical Center.
Stored serum was analyzed for expression of IBDassociated antibodies, including ASCA, anti-OmpC, anti-CBir1, and pANCA in a blinded fashion by enzyme-linked immunosorbent assay (ELISA), as previously described. 25, 28 Antibody levels were determined and results expressed as ELISA units (EU/ml), which are relative to a Cedars-Sinai Laboratory (OmpC-IgA and anti-CBir1) or a Prometheus Laboratory standard (ASCA-IgA and IgG) derived from a pool of patient sera with well-characterized disease found to have reactivity to these antigens. Qualitative positivity to any antibody was defined as being greater than cutoff values greater than 2 standard deviations above mean control titers for each assay. Qualitative positivity for ASCA was considered separately for having positivity to either or both of the IgA or IgG antibodies. The magnitude of quantitative antibody seroreactivity was logarithmically transformed and standardized. All assays were performed blindly without knowledge of patient clinical characteristics. Similarly, clinical course after IPAA was assessed without knowledge of the patient's serologic profile.
Statistical Analysis
Statistics were performed by using JMP ® , version 5.1 and SAS ® , version 8.2 (both from the SAS Institute, Inc., Carey, NC). For continuous covariates, medians were compared with the use of Wilcoxon nonparametric tests. Categorical variables were compared with the use of chi-squared or Fisher's exact test. Serologic statistical analyses were performed for log-transformed quantitative seroreactivity, as well as for qualitative seroreactivity using prespecified thresholds described above (positive/negative). The Cox proportional hazards model was used to simultaneously evaluate all factors; those factors with simultaneous P<0.15 were retained in the final model after stepwise backward elimination. Hazard ratios (HR) and 95 percent confidence intervals (CI) were calculated. The performance of the multivariate model was evaluated with the Concordance (C) statistic. The risk of CD development over time was plotted by using the Kaplan-Meier method. The log-rank test was used to compare these incidence curves to assess the role of serologic risk factors in the cumulative incidence of CD over time. All hypothesis testing was two-sided with P value of <0.05 considered statistically significant.
RESULTS
Patient Demographics and Clinical Characteristics
Patient demographic and clinical characteristics of the 238 study patients are shown in Table 1 . All patients underwent stoma closure and no patients were "lost" to followup. A majority of the patients were male. Of the 199 patients with medically unresponsive disease, 34 (14 percent) were steroid-dependent and 165 (83 percent) were refractory to other immunosuppressive therapy, including thiopurines (n=145), cyclosporine (n=96), and/or infliximab (n=30). Forty patients (17 percent) had EIMs associated with their disease, including arthritis (n=26), skin disease (n=7), PSC (n=5), or uveitis (n=1). Twenty-four of 174 patients (14 percent) with pancolitis had backwash ileitis. Fifty-seven patients (25 percent) had a family history of IBD. There were 29 patients with affected first-degree relatives and 28 additional patients with more distant affected relatives. Among 20 patients with a family history of CD, 7 (35 percent) had affected first-degree relatives and 13 (65 percent) had more distant affected family members. Although the majority of patients had surgery for medically refractory disease, IPAA was performed in 26 patients for dysplasia and 13 patients for an established carcinoma.
Ulcerative Colitis, IBD-Unspecified, and Indeterminate Colitis Surgery was initially performed for UC in 195 patients (82 percent) and IBD-U in 43 patients (18 percent). Within the IBD-U group were patients with discontinuous colonic inflammation (n=18), small-bowel inflammation not considered to be backwash ileitis (n=12), deep ulceration noted during colonoscopy or leading to colon perforation (n=7), and previous history of anal disease (n=6). Twentyseven of the UC patients (14 percent) were reclassified as IC after colectomy. Reasons for a postoperative change of diagnosis from UC to IC included histopathologic evidence of transmural inflammation on the colectomy specimen (n=23) and severe mesenteric thickening noted at surgery (n=4). In total, there were 168 patients (71 percent) with UC and 70 patients (29 percent) with IBD-U or IC.
Crohn's Disease Development
After a median follow-up time after ileostomy closure of 47 (range, 1-142) months, 16 patients developed CD, representing an overall incidence of 7 percent. Median time to diagnosis of CD was 19 (range, 1-41) months. One patient developed CD of the pouch and proximal limb of the ileostomy one month after IPAA creation. All of the remaining patients developed CD more than three months after ileostomy closure. CD was diagnosed on the basis of afferent ileal limb disease (n=12) and new perianal disease (n=4). Ten patients were maintained on immunosuppressive therapy, two patients were controlled with antibiotics alone, and four patients required a diverting ileostomy to control persistent symptoms after failing aggressive immunosuppression.
Serologic Analysis
Serum pANCA, anti-OmpC, ASCA, and anti-CBir1 were detected in 171 patients (72 percent), 53 patients (22 percent), 48 patients (20 percent), and 46 patients (19 (Table 3) . Within the 48 ASCApositive patients were 32 patients who were ASCA IgA+, 16 patients who were ASCA IgG+, and 7 patients who expressed both forms of ASCA. There were no significant differences in clinical characteristics in patients who were serologically positive compared to patients who did not express these markers (data not shown).
Clinical and Serologic Factors Predicting
Postoperative CD Demographic and clinical factors among the CD cases and non-CD control subjects in the entire patient group are shown in Table 1 . Fifty percent of the CD group had a family history of IBD compared with 22 percent of those without CD (P=0.07). Patients developing CD after IPAA were significantly more likely to have a family history of CD (P = 0.0008) vs. patients who did not develop postoperative CD. Family history score also was higher in those with a CD diagnosis (P=0.03). There were no other significant differences in demographic and clinical factors between the CD and non-CD patient groups. The association between serologic marker expression and clinical course after IPAA is shown in Table 2 . Univariate analysis of quantitative and qualitative seroreactivity to IBD-associated antibodies did not show significant differences among those with CD compared with non-CD control subjects. However, ASCA IgA positivity and pANCA levels were increased among those with CD (P=0.055 and 0.12, respectively). OmpC levels tended to be higher among those without CD (P=0.1).
The Cox multivariate proportional hazards model retained three factors with P<0.15, including family history of CD, ASCA IgA+, and pANCA+ ( Table 3 ). The two significant factors that were independently associated with the development of CD after IPAA were family history of CD (hazard ratio (HR) = 8.4; 95 percent CI, 2.96-24.1; P<0.0001), and ASCA-IgA+ (HR=3.14; 95 percent CI, 1.1-9.81; P=0.04). CD developed in only 8 of 198 patients (4 percent) without these predictors vs. 8 of 40 (20 percent) in those with at least one of these factors. This difference in CD development after IPAA response based on family history of CD and preoperative ASCA IgA serologic expression was highly significant (P=0.002). The positive predictive value (PPV) and the negative predictive value (NPV) of family history of CD in our population were 0.3 and 0.95, respectively. Those for ASCA IgApositivity were 0.17 and 0.94, respectively. When both factors were present, PPV and NPV were 0.67 and 0.94.
The cumulative incidence of developing CD over time in patients with these two risk factors is shown in Fig. 1 . The cumulative risk of developing CD in patients who did not have a risk factor (n=198) was only 4 percent. Compared to the no risk factor patient group, patients with a single risk factor (n=37) had a significantly higher cumulative incidence of CD (16 percent; P=0.004). Furthermore, patients with two or more risk factors (n= 3) had a significantly higher cumulative incidence of CD (67 percent) compared with patients with only one risk factor (P=0.02) or no risk factor (P<0.001).
There was no significant difference in the incidence of CD development between the UC (7 percent), IBD-U (5 percent), and IC (7 percent) patient groups. Using multivariate analysis of clinical and serologic factors in the UC patient subgroup, we found that although family history of CD was again predictive (HR=6.8; 95 percent CI, 2.01-20.5; P=0.003) of postoperative CD, the association of ASCA-IgA positivity approached but did not reach statistical significance (HR=3.5; 95 percent CI, 0.94-10.4; P=0.06). No statistical modeling was performed in the IBD-U or IC patient groups because of the paucity of CD events in these groups. 
DISCUSSION
The development of CD after IPAA is associated with both a significantly lower quality of life 29 and higher incidence of ultimate pouch failure. 5, 6, 8, 9, 30, 31 The identification of possible predictors of CD in these patients is therefore important for proper surgical management and prognostication for these patients. We identified two independently significant predictors of postoperative CD: a family history of Crohn's disease and seroreactivity to ASCA IgA. Furthermore, we found that those with a postoperative change in diagnosis had a median of only five months from ileostomy closure before the diagnosis of CD was made. The study described herein was prospective in design, all procedures were performed by a single surgeon in one hospital, and all patients had consistent, longitudinal follow-up.
Published retrospective studies have attempted to identify risk factors for the development of CD. Potential risk factors have included IC, 8, [13] [14] [15] [16] female gender, and perianal disease. 4 Many of these previous reports have been hampered by their retrospective design, suboptimal patient follow-up, and referral center bias. A recent prospective study at a tertiary pouchitis clinic showed that both a long duration of IPAA and active smoking were risk factors for postoperative CD development and that family history of IBD was not a significant factor; serologies were not assessed in that study. 17 Although smoking is an established risk factor for Crohn's disease, our study did not find smoking to be a risk factor for CD.
The reason for this is unclear, although the overall incidence of "smokers" in our UC population is roughly half that of the population studied by Shen et al. 17 suggesting a potential Type II error in the present study.
The prevalence of CD after IPAA in the present study (7 percent) compares favorably with the 1 to 14 percent reported in other series. [3] [4] [5] [6] [7] [8] Mechanisms accounting for the change in diagnosis from UC to CD are unknown. Although most likely related to the inability to accurately distinguish the two diseases before surgery, particularly in the fulminant phase, 13 it is interesting to speculate that the change in diagnosis reflects an inherent biologic behavior. In a large population study, almost 3 percent of nonoperated patients with UC evolved into CD, 32 similar to the incidence of CD development in the current prospectively followed patient cohort. A recent report by Melmed and colleagues 33 showed that two clinical factors (nonbloody diarrhea and weight loss >10 percent at initial clinical presentation) independently predict a change in diagnosis in the unoperated patient with UC. No significant association was found, however, with any serologic expression and diagnosis change. In the present study, CD development after IPAA was influenced by family history of CD and ASCA IgA seropositivity. It therefore appears that unoperated and operated patients with UC have different risk factors for CD development. This finding reinforces the theory that UC is likely a heterogeneous inflammatory disorder with different immunopathogenetic mechanisms. A better understanding of these processes may help gain insight into the etiology of UC and perhaps provide possible therapeutic options for its treatment.
The incidence of a family history of IBD in this study (24 percent) compares favorably to another surgical study that commented on this clinical factor. 34 A novel finding in the current study was the significant influence of family history of CD on the eventual development of CD after surgery. Although Shen et al. 17 did not find an association between "family history of IBD" with CD post-IPAA, we found that detailing the history further by type of IBD was strongly associated with a postoperative change in diagnosis. Furthermore, our findings are corroborated by our use of the family history score that attributed a higher weight to first-degree family members compared with more distant relatives with IBD. A positive family history has been found to be the strongest risk factor for the initial development of IBD, and first-degree family members are at highest risk. 35, 36 Preoperative evaluation of patients with UC who are contemplating an IPAA should include a detailed family medical history to provide the best possible prognostic information to patients and their families.
In addition to the use of clinical, endoscopic, radiologic, and histologic evaluation, specific seromarker expression has been used to help classify patients with Overall p < 0.0001 (log-rank) p = 0.004 FIGURE 1. Effects of family history of Crohn's disease (CD) and expression of anti-Saccharomyces cerevisiae (ASCA)-IgA on the cumulative incidence of CD after ileal pouch-anal anastomosis (IPAA). The risk of developing CD after IPAA among patients with both factors was significantly higher than in patients who had did not have either factor or who had only one factor. IBD as UC or CD. In the surgical patient, preoperative seromarker expression has been associated with chronic pouch inflammation after IPAA for IC 37 and the development of chronic pouchitis after IPAA in UC. 38 Little is known regarding the significance of serologic studies and the development of CD after IPAA. In the only study to date of a highly selected group of patients with UC, Dendrinos and coworkers 39 showed that ASCApositive patients were at greater risk of developing postoperative pouch fistulas (and presumably CD) than ASCA-negative patients. This study did not comment on the distribution of IgA and IgG ASCA subtypes, and sera were drawn at varying time points after surgery. Data from the current study showed a strong association between preoperative ASCA-IgA expression and the onset of CD after IPAA in patients with UC and IC. Although the mechanisms by which ASCA-IgA positivity influences postoperative inflammation are unknown, it is well known that ASCA expression is associated with aggressive disease course, including the need for small-bowel surgery, in both adults and children with CD. 21, 28, 40 Serologic testing should be strongly considered in the preoperative evaluation of patients requiring IPAA.
There are three milestones when the diagnosis of CD should be considered in a patient with UC or IC who is undergoing IPAA: before colectomy, after histologic review of the resected specimen, and after ileostomy closure. Although the presence of granulomas is conclusive, 41 many studies have included "minor" pathologic criteria, such as transmural inflammation, discontinuous disease, and fissuring ulcers in the surgical specimen, to establish the diagnosis of CD immediately after colectomy. 7, 9, 12, 15, 16, 34, 39, [42] [43] [44] [45] [46] [47] We consider patients with these minor criteria to have IC and not CD, because these features can not only be observed in fulminant UC but also may reflect treatment effect. Furthermore, we found no significant difference in clinical outcome (i.e., CD development) after IPAA between the UC, IBD-U, and IC patient subgroups. Patients with preoperative clinical features of UC who have minor CD features on the colectomy specimen seem to have an uncomplicated course after IPAA, confirming the results of other investigators. 10, 12, 44, 46, 48 To introduce uniform diagnostic criteria, we recommend that future studies examining the results of IPAA in patients with CD only include patients with IBD with strictly defined characteristics of CD, i.e., granulomas on endoscopic biopsies or in the resected specimen, those with active anal disease, or patients with significant small-bowel inflammation.
Older studies have suggested that most patients who develop CD in their pouch required fecal diversion for symptom control. 10, 11, 42 One-quarter of the patients with CD in this study required a permanent diverting ileostomy, corresponding well to the 34 percent stoma rate noted in another more recent study. 7 Two publica-tions in the last few years have demonstrated that the majority of patients who develop CD after IPAA do not require fecal diversion because they can be successfully managed by using medical measures alone. 49, 50 These results can only be expected to improve with the increasing use of potent therapies, such as biologic agents.
What implications do our findings have for a physician counseling a patient with UC facing colectomy? Although it is unlikely that the presence of one of these two predictors would alone alter a decision to undergo IPAA, prognostication of outcomes might be modified in the patient with ASCA seropositivity or a family history of CD to include the possibility of postoperative CD and its inherent risk for pouch failure. In addition, close attention to a thorough preoperative diagnostic workup to exclude CD is warranted among those with risk factors. Finally, postoperative evaluation for CD among symptomatic patients after IPAA may be warranted so that CD can be correctly diagnosed and treated.
CONCLUSIONS
This study comprehensively describes clinical and serologic risk factors for CD among patients with UC or IC who are undergoing IPAA. Our findings suggest that among these patients, those with a family history of CD or those who have seropositivity for ASCA IgA should be carefully evaluated for CD preoperatively. Validation of our findings will help to determine the prognosis of patients with these identified risk factors to optimize preoperative counseling.
